Prosecution Insights
Last updated: April 19, 2026
Application No. 18/032,014

DRUG DELIVERY DEVICE ASSEMBLY AND ACCESSORY FOR DRUG DELIVERY DEVICE

Final Rejection §102§112
Filed
Apr 14, 2023
Examiner
STIGELL, THEODORE J
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Amgen, Inc.
OA Round
2 (Final)
78%
Grant Probability
Favorable
3-4
OA Rounds
3y 4m
To Grant
93%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allow Rate
975 granted / 1245 resolved
+8.3% vs TC avg
Moderate +15% lift
Without
With
+14.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
45 currently pending
Career history
1290
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
31.3%
-8.7% vs TC avg
§102
31.7%
-8.3% vs TC avg
§112
21.1%
-18.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1245 resolved cases

Office Action

§102 §112
DETAILED ACTION Response to Amendment Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 17-20, 22, 25, 27, 29-31 and are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. In regard to claim 17, there is no original disclosure of a donut-shaped reflective surface with a base portion and cylindrical shaped inner surface extending from the base portion as is now recited. This limitation appears to be an attempt to capture the features of the embodiment in Figures 7-8 but this embodiment does not include a base portion with a cylindrical shaped inner surface extending from the base portion. The embodiment includes an adapter 252 that defines a cylindrical inner surface 253 but these features do not cover the recited limitations. The dependent claims are rejected by virtue of their dependency on the rejected independent claim. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 17-20, 22, 25, 27, 29-31 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In regard to claim 17, the limitation “a cylindrical shaped inner surface extending from the base portion” in combination with the limitation “a reflective surface extending from the base portion” renders the claim indefinite. The claim would appear to make more sense if the reflective surface is recited as extending from the cylindrical shaped inner surface instead of the base portion because the inner surface extends from the base. See Figure 2 of the instant application. The dependent claims are rejected by virtue of their dependency on the rejected independent claim. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 17 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Rudin (US 4,208,588). In regard to claim 17, Rudin discloses an accessory (6) for a drug delivery device (2; the examiner notes that the drug delivery device is functionally claimed; 2 is highlighted for illustrative purposes only), comprising: a base portion (20); a cylindrical shaped inner surface (10) extending from the base portion along a longitudinal axis, the base portion configured to be operably coupled with the drug delivery device (see at least col. 3, line 40- col. 4, line 7), the drug delivery device having: an injector housing having a body with a proximal end, a distal end, and at least one window, a needle assembly at least partially disposed within the body, the needle assembly comprising a syringe barrel containing a medicament and a needle or a cannula, at least a portion of the syringe barrel positioned such as to be visible through the at least one window[[;]], and a drive assembly at least partially disposed within the body and operably coupled with the needle assembly to urge the medicament through the needle or cannula during an injection sequence (drug delivery device is functionally recited); and a reflective surface (16,17) extending from the base portion and positioned with respect to the window such as to increase visibility of the syringe barrel (see at least col. 4, lines 3-7), wherein (b) the reflective surface is donut shaped (see at least Figs. 2-3 and 5; the examiner maintains that any curved shaped is donut-shaped). Allowable Subject Matter Claims 18-20, 22, 25, 27, and 31 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim 17 would be allowable if the (b) option of the claim was cancelled and furthermore the 112(b) rejection was resolved by reciting that the reflective surface extends from the cylindrical shaped inner surface. In regard to claims 29-30, Rudin does not disclose the features of the base. These claims are still subject to a 112(a) rejection. Response to Arguments Applicant's arguments filed 3/11/2026 have been fully considered but they are not persuasive. The applicant’s argument that Rudin fails to disclose a donut shaped reflective surface is not persuasive. Any curved shape can be considered donut shaped. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to THEODORE J STIGELL whose telephone number is (571)272-8759. The examiner can normally be reached M-F 9-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Tsai can be reached at 571-270-5246. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. THEODORE J. STIGELL Primary Examiner Art Unit 3783 /THEODORE J STIGELL/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Apr 14, 2023
Application Filed
Feb 04, 2026
Non-Final Rejection — §102, §112
Mar 11, 2026
Response Filed
Mar 25, 2026
Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594379
Backflow Prevention Mechanism for Drug Delivery Device
2y 5m to grant Granted Apr 07, 2026
Patent 12589231
SUBCUTANEOUSLY CHANGEABLE VASCULAR ACCESS PORT
2y 5m to grant Granted Mar 31, 2026
Patent 12582440
INSTRUMENT ENTRY GUIDE
2y 5m to grant Granted Mar 24, 2026
Patent 12582811
Instrument Delivery Device with Nested Housing
2y 5m to grant Granted Mar 24, 2026
Patent 12569672
DEVICE, SYSTEM AND METHOD FOR TREATING A CORNEAL TISSUE
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
78%
Grant Probability
93%
With Interview (+14.6%)
3y 4m
Median Time to Grant
Moderate
PTA Risk
Based on 1245 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month